Examples of using Pediatric patients in English and their translations into Hebrew
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
Promethazine hydrochloride tablets, USP are contraindicated for children under 2 years of age(see WARNINGS- Black Box Warning and Use in Pediatric Patients).
The safety and effectiveness of dobutamine injection for use in pediatric patients have not been studied.
its effectiveness has been tested by many pediatric patients.
Antiemetics should not be used in vomiting of unknown etiology in children and adolescents(see WARNINGS-Use in Pediatric Patients).
The use of intravenous famotidine in pediatric patients less than 1 year of age with GERD has not been adequately studied.
The pharmacokinetic parameters for pediatric patients, ages>3 months-15 years, are comparable to those obtained for adults.
Safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials(see WARNINGS, Withdrawal).
The safety and efficacy of ELELYSO were assessed in fourteen pediatric patients with Type 1 Gaucher disease in two clinical trials.
In contrast, pediatric patients 0-3 months of age had famotidine clearance values that were 2- to 4-fold less than those in older pediatric patients and adults.
Pediatric patients should receive a thorough eye exam before the age of 2,
These studies suggest a starting dose for pediatric patients 1-16 years of age as follows.
Project Sunshine's programs fill a gap in pediatric patients' lives by bringing the joys of the outside world into the hospital.
The safety of the drug for long-term, chronic use as adjunctive therapy for nocturnal enuresis in pediatric patients 6 years of age or older has not been established;
sometimes death, in pediatric patients.
Similarly, in pediatric patients 1-15 years of age,
Published uncontrolled clinical studies in pediatric patients have employed doses up to 1 mg/kg/day for peptic ulcer
Use of famotidine in pediatric patients< 1 year of age is supported by evidence from adequate and well controlled studies of famotidine in adults, and by the following studies in pediatric patients< 1 year of age.
Table 6 presents pharmacokinetic data from clinical trials and a published study in pediatric patients(< 1 year of age; N= 27) given famotidine I.V. 0.5 mg/kg and from published studies of small numbers of pediatric patients(1 to 15 years of age) given famotidine intravenously.
FDA is continuing to review available clinical trial data for pediatric patients with depression and other psychiatric disorders to try to determine whether there is evidence that some
data in pediatric patients are insufficient to establish percent response with dose and duration of therapy.
